Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks

SS-31 versus MOTS-c

SS-31 vs MOTS-c: A Mitochondria-Targeted Drug and an Endogenous Peptide Compared

SS-31 (elamipretide) has an FDA label for Barth syndrome; MOTS-c has no human treatment study. What each evidence base shows, including SS-31 trials that missed their primary endpoints.

Save
FeatureSS-31MOTS-c
OriginSynthetic tetrapeptide, D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH2 (Forzinity label)16-amino-acid peptide encoded in mitochondrial DNA (PMID 25738459)
Developed byElamipretide, marketed as Forzinity by Stealth BioTherapeutics (label)Reported in 2015 by Lee and colleagues in Cell Metabolism (PMID 25738459)
Reported targetCardiolipin, a phospholipid of the inner mitochondrial membrane (PMID 23813215)Reported to inhibit the folate cycle and activate AMPK in cells and mice; no receptor established (PMID 25738459)
Where it acts, per the sourcesThe label says it localises to the inner mitochondrial membraneIn mice, skeletal muscle appears to be the primary target organ (PMID 25738459)
Human treatment studiesRandomised trials in Barth syndrome (PMID 33077895) and primary mitochondrial myopathy (PMID 32096613; PMID 37268435)None found giving MOTS-c; human studies measure the body's own MOTS-c (see the MOTS-c page)
Primary endpoints in the larger trialsBarth syndrome part 1: neither primary endpoint met (PMID 33077895). MMPOWER-3, 218 people with primary mitochondrial myopathy: primary endpoints not met (PMID 37268435)Not applicable
FDA statusAccelerated approval as Forzinity on 19 September 2025 (Drugs@FDA, application 215244) to improve muscle strength in Barth syndrome patients weighing at least 30 kgNo approved product found: DailyMed drug-name search for MOTS-c, 6 November 2026
FDA bulk drug substances page (content current as of 22 April 2026)Not named thereListed as MOTs-C. FDA safety statement: see What are the risks?
Labelled dose40 mg subcutaneously once daily; 20 mg once daily for adults with severe kidney impairment (eGFR below 30 mL/minute) who are not on dialysis. The label says there is "insufficient information to recommend a dosage regimen in adults with eGFR less than 30 mL/minute and on dialysis"No human dose
Route in studiesSubcutaneous in the label and the trials aboveIntraperitoneal injection in mouse and rat studies (PMID 33473109); no human route
Studied togetherNo clinical trial: PubMed, 6 November 2026, MOTS-c[tiab] AND (SS-31[tiab] OR elamipretide[tiab]) AND (clinical trial[pt] OR randomized controlled trial[pt]): 0 recordsSame search
ClassMitochondria-targeted synthetic peptideMitochondrial-derived peptide

SS-31 (elamipretide) and MOTS-c are both discussed as peptides that act on mitochondria, but their evidence bases are very different. SS-31 is a synthetic peptide with an FDA label for one rare disease. MOTS-c is a peptide encoded in mitochondrial DNA that has been studied in animals and measured in people, and has not been given to people in any published study we found. The monographs hold the detail: SS-31 and MOTS-c.

What each is said to do

SS-31. The Forzinity label describes elamipretide as "a mitochondrial cardiolipin binder that localizes to the inner mitochondrial membrane and improves mitochondrial morphology and function". In the test tube, a fluorescent analogue of SS-31 bound with high affinity to cardiolipin; in rats, pretreatment with SS-31 protected the folded inner membranes (cristae) of kidney mitochondria during ischaemia (PMID 23813215). A cross-linking study found that SS-31 interacts with proteins that are all known cardiolipin binders (PMID 32554501).

MOTS-c. The 2015 paper reports that its cellular actions "inhibit the folate cycle and its tethered de novo purine biosynthesis, leading to AMPK activation", and that in mice it prevented diet-induced obesity and insulin resistance (PMID 25738459). Doses and results are on the MOTS-c page. They are mouse and rat findings, given by intraperitoneal injection (PMID 33473109).

What the human evidence shows

SS-31. The FDA approved Forzinity on 19 September 2025 under accelerated approval (Drugs@FDA, application 215244; label, effective 10 December 2025). It is indicated "to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg", an accelerated approval "based on an improvement in knee extensor muscle strength, an intermediate clinical endpoint", and continued approval "may be contingent upon verification and description of clinical benefit in a confirmatory trial".

The trials behind it, and the other trials, were mixed:

  • Barth syndrome, phase 2/3 crossover (12 people, 40 mg a day for 12 weeks). "In part 1 neither primary endpoint was met" (PMID 33077895). The label says elamipretide "was not superior to placebo" on the 6-minute walk and fatigue endpoints, and that increases in knee muscle strength "were not observed during the randomized trial but were observed during the extension period", which had no control group. Ten people continued in the extension.
  • Primary mitochondrial myopathy, MMPOWER-2 (30 adults, 40 mg a day for 4 weeks). The 6-minute walk difference was 19.8 m (P = 0.0833), not statistically significant (PMID 32096613).
  • Primary mitochondrial myopathy, MMPOWER-3 (218 adults, 40 mg a day for 24 weeks). The study "did not meet its primary endpoints" on the 6-minute walk (difference -3.2 m, P = 0.69) or on total fatigue (PMID 37268435). The registry record lists the study as terminated, with results posted: 109 people started on elamipretide and 109 on placebo in the double-blind period, with serious adverse events in 5 and 3 people respectively and no deaths (ClinicalTrials.gov NCT03323749).

MOTS-c. No published study gave MOTS-c to people. The human studies found measure the body's own MOTS-c, for example before and after cycling in 10 young men (PMID 33473109). There is no human dose, no human safety data and no approved product. See the MOTS-c page for the searches.

Together. A PubMed search on 6 November 2026 for "MOTS-c"[tiab] AND (SS-31[tiab] OR elamipretide[tiab]) AND (clinical trial[pt] OR randomized controlled trial[pt]) returned 0 records, so no clinical trial has tested them together.

What are the risks?

For SS-31, from the Forzinity label:

  • Benzyl alcohol. The product contains 20 mg of benzyl alcohol per mL. Serious and fatal reactions, including gasping syndrome, have been reported in low-birth-weight and preterm neonates given benzyl-alcohol-containing drugs intravenously, and Forzinity is not approved for use in neonates.
  • Hypersensitivity. Serious allergic reactions requiring emergency treatment have been reported, including skin reactions (rash, papular lesions, eczematous dermatitis) and cough. The label says "Reactions may occur within minutes to months after treatment initiation" and "Monitor patients for signs and symptoms of hypersensitivity reactions during treatment". It says to consider discontinuation "if persistent or severe skin reactions develop". Serious hypersensitivity to elamipretide or its excipients is a contraindication, and patients who have had a serious reaction should not be rechallenged.
  • Injection-site reactions. In the crossover trial, any local administration reaction occurred in 12 of 12 people on elamipretide and 8 of 12 on placebo; injection-site erythema occurred in 12 of 12 and 3 of 12.
  • Eosinophilia. Eosinophil counts rose in studies lasting 30 days or more, peaking around 90 days and returning to baseline after 6 to 12 months of continuous use or after stopping; the label says the rise was not associated with clinical manifestations.
  • Limits of the evidence. The label says safety and effectiveness have not been established in patients weighing less than 30 kg, and that studies did not enrol people with Barth syndrome aged 65 or over.

For MOTS-c, there are no human safety data. FDA's page "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (content current as of 22 April 2026) lists MOTs-C under "Bulk drug substances nominated but withdrawn", which it describes as substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators". Compounding is the preparation of a medicine by a pharmacist or doctor from its ingredients. FDA's entry for MOTs-C reads: "Compounded drugs containing MOTs-C may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration. FDA lacks important information regarding any safety issues raised by MOTs-C, including whether it would cause harm if administered to humans." In a rat model of type 2 diabetes, MOTS-c-treated heart mitochondria showed increased reactive oxygen species (PMID 40661667, see the MOTS-c page).

UK regulatory position

This site gives no legal advice or sourcing information and does not sell anything. Rules on unauthorised medicines exist in the Human Medicines Regulations 2012. Whether a particular product is a medicinal product under regulation 2 depends on its specifics, including how it is presented and how it functions. For questions about medicines speak to a GP or pharmacist; problems with a medicine can be reported to the MHRA through the Yellow Card scheme.

Verdict — research-question matching

The two are not competing options: one is a drug with an FDA label for a rare disease, the other a peptide with mouse findings and no study giving it to people. SS-31 has a label and randomised trials, but its larger trials missed their primary endpoints and the label rests on an intermediate measure of muscle strength. MOTS-c has no human treatment data. No study has tested the two together.

References

Peer-reviewed sources for the claims above. Where an editor has verified study type, sample size, outcome and limitation, the citation is rendered as a card; otherwise as a plain reference. Links open PubMed or the journal DOI.

  1. Birk AV, Liu S, Soong Y, et al.. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. 2013;24(8) :1250-61 doi:10.1681/ASN.2012121216 · PMID: 23813215
  2. Chavez JD, Tang X, Campbell MD, et al.. Mitochondrial protein interaction landscape of SS-31. Proceedings of the National Academy of Sciences. 2020;117(26) :15363-15373 doi:10.1073/pnas.2002250117 · PMID: 32554501
  3. Lee C, Zeng J, Drew BG, et al.. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3) :443-454 doi:10.1016/j.cmet.2015.02.009 · PMID: 25738459
  4. Reid Thompson W, Hornby B, Manuel R, et al.. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in Medicine. 2021;23(3) :471-478 doi:10.1038/s41436-020-01006-8 · PMID: 33077895
  5. Karaa A, Haas R, Goldstein A, et al.. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. Journal of Cachexia, Sarcopenia and Muscle. 2020;11(4) :909-918 doi:10.1002/jcsm.12559 · PMID: 32096613
  6. Karaa A, Bertini E, Carelli V, et al.. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. 2023;101(3) :e238-e252 doi:10.1212/WNL.0000000000207402 · PMID: 37268435
  7. Pham T, Taberner A, Hickey A, et al.. Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart. Frontiers in Physiology. 2025;16 :1602271 doi:10.3389/fphys.2025.1602271 · PMID: 40661667
  8. Reynolds JC, Lai RW, Woodhead JST, et al.. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12(1) :470 doi:10.1038/s41467-020-20790-0 · PMID: 33473109
Published: 2026-08-05Last updated: 2026-11-06
  • Correction (2026-11-06): Corrected 6 November 2026 after a dose and citation audit: the elamipretide approval was misdated and its larger trials, which missed their primary endpoints, were described as culminating in approval; label warnings and FDA's MOTs-C statement were added; legal statements were replaced.

If you spot an error or have new evidence to suggest, please use our corrections policy.

Continue reading

Stack

Epitalon + Humanin + MOTS-c — Research Evidence Review: What Has Been Studied

Evidence review of Epitalon, Humanin and MOTS-c: lifespan results in mice, small human epitalon reports, no study of the three together, and what is unknown.

Stack

MOTS-c + AOD-9604 — Research Evidence Review: Mitochondrial & Lipolytic Mechanisms

Evidence review of MOTS-c and AOD-9604: what has been studied in animals and in people, what is unknown, and the fact that no study has tested them together.

Stack

SS-31 + Humanin — Research Evidence Review: Mitochondrial Mechanisms

Evidence review of SS-31 (elamipretide, FDA label for Barth syndrome) and Humanin (no human dosing studies): what is known, the trial results and what is unknown.

Peptide

SS-31 (Elamipretide) — Cardiolipin-Targeted Mitochondrial Peptide

Elamipretide (SS-31) has an FDA label as Forzinity for Barth syndrome. The labelled dose, trial results in mitochondrial myopathy, heart failure and eye disease, risks and unknowns.

Peptide

MOTS-c — Mitochondrial Open Reading Frame 12S rRNA-c

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. Mouse and rat findings, human studies of the body's own MOTS-c, no study giving it to people, and what is unknown.

Comparison

MOTS-c vs AOD-9604 — Mitochondrial Peptide vs Growth Hormone Fragment

MOTS-c vs AOD-9604: what each has been studied for in animals and in people, the doses published studies used, regulatory and WADA facts, and what no study has compared.

Comparison

MOTS-c vs Humanin — Two Mitochondrial-Derived Peptides Compared

MOTS-c and humanin are peptides encoded in mitochondrial DNA. Compared: what each does in cells and rodents, what has been studied in people, and one cancer-related safety signal.